Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iodine-125 Seed Implantation Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
ChiCTR2300078050Phase 2Recruiting
- Sponsor
- Hebei General Hospital
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Hebei General Hospital. Primary endpoint: Disease control rate. Started Jul 2023; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2300078050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078050.